All In Biotech

Drug Trial Radar · NCT07932795

Study of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe Eczema

A Phase 1b, Open Label Study Without Comparator to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses (MAD) of M5542 in Patients With Eczema

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Dec 20, 2026

Primary completion

Aug 14, 2028

Study completion Aug 14, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the safety and tolerability of multiple ascending dose (MAD) of M5542 in participants with Eczema.

Conditions

  • Eczema

Interventions

  • M5542Biological

    Participants will receive loading dose of M5542 followed by maintenance doses as determined by the Safety Monitoring Committee (SMC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Study Intervention DiscontinuationTime frame: From Day 1 (Baseline) up to end of Safety Follow-Up (Week 29)
  2. Number of Participants with Clinically Significant Changes from Baseline in Safety Laboratory AssessmentsTime frame: From Day 1 (Baseline) up to end of Safety Follow-Up (Week 29)
  3. Number of Participants with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs)Time frame: From Day 1 (Baseline) up to end of Safety Follow-Up (Week 29)
  4. Number of Participants with Clinically Significant Changes from Baseline in Vital SignsTime frame: From Day 1 (Baseline) up to end of Safety Follow-Up (Week 29)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Darmstadt, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.